{
    "clinical_study": {
        "@rank": "94275", 
        "arm_group": {
            "arm_group_label": "Liposomeal curcumin ascending dose  phase 1b", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is a single center in patient/outpatient, uncontrolled dose escalating study in cancer\n      patients to evaluate the safety, tolerability and pharmacokinetic (PK) profiles of body\n      surface area adjusted doses of liposomal curcumin administered intravenously as an 8 hour\n      infusion once weekly for 8 weeks."
        }, 
        "brief_title": "A PHASE Ib DOSE ESCALATION STUDY OF LIPOCURC IN PATIENTS WITH CANCER", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Patients With Advanced Cancer Who Have Failed Standard of Care Therapy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and Female patients >18 years with a histologically/cytologically confirmed\n             diagnosis of locally advanced or metastatic cancer ,for whom no anti-tumor therapy of\n             proven benefit is available at study enrollment. ECOG 0-2. Life expectancy of at\n             least 3 months. Measurable or non-measurable disease according to RECIST v1.1\n             criteria. Patients should have at least one measurable lesion  or disease  which is\n             non-measurable  but can be clearly be evaluated  for response.Adequate bone marrow\n             function as evidenced  by an absolute neutrophil count :1500 cell/ul. Hb greater than\n             9.5 g/dLand a platelet count greater than  100,000/ uL. Renal function>50ml/min with\n             estimated creatinine clearance(eCcr) using the Cockcroft -Gault formula or serum\n             creatinine<1.5 mg/dL.Adequate hepatic function as evidenced by serum total bilirubin\n             <3.0 mg/dL, and AST and ALT less than 5 times the upper limit of normal(ULN). Signed\n             informed consent.\n\n        Exclusion Criteria:\n\n        Patients with lymphoma ,hematological cancer or glioblastoma multiforme. Active infection\n        , or a fever >38.5C within three days prior to the first day of study drug dosing.Current\n        or past history evidence  of disease (hemolytic diathesis, hemochromatosis ) that could be\n        exacerbated by administering  liposomal curcumin.Currently on coumidin or couminin\n        derivatives(oral anticoagulants), or any medications classified as cytochrome p450\n        inhibitors or inducers.Last systemic therapy less than three(3) weeks before (six weeks if\n        treatment was with BCNU or CCNU). Unresolved toxicities  from prior systemic anti-cancer\n        therapy except symptomatic motor  or sensory neuro-toxicities  NCI-CTC Grade <2.\n        Clinically significant ECG abberrations according to the discretion of the investigator.\n        Left ventricular ejection fraction (LVEF) <50%.\n\n        -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02138955", 
            "org_study_id": "Lipocurc1002/P-1-010", 
            "secondary_id": [
                "0011594-24", 
                "SPP1002"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Liposomeal curcumin ascending dose  phase 1b", 
            "intervention_name": "Liposomeal curcumin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Curcumin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 14, 2014", 
        "location": [
            {
                "contact": {
                    "email": "M.Schachner@salk.at", 
                    "last_name": "Michaela Schachner", 
                    "phone": "011 43(0)662 4482 2898"
                }, 
                "facility": {
                    "address": {
                        "city": "Salzburg", 
                        "country": "Austria", 
                        "zip": "5020"
                    }, 
                    "name": "3. Medizinische Universitatesclinik, Haematologie, Internistische Onkologie"
                }, 
                "investigator": {
                    "last_name": "Richard Greil, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "M.Schachner@salk.at", 
                    "last_name": "Michaela Schachner", 
                    "phone": "011 43 (0) 662 4482 2898"
                }, 
                "facility": {
                    "address": {
                        "city": "Salzburg", 
                        "country": "Austria", 
                        "zip": "5020"
                    }, 
                    "name": "3 Medicizinische Universitatsklinik Hematologie,Internistische Onkologie"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_arms": "1", 
        "official_title": ": A PHASE Ib DOSE ESCALATION STUDY ON THE SAFETY, TOLERABILITY AND ACTIVITY OF LIPOSOMAL CURCUMIN IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC CANCER", 
        "other_outcome": {
            "measure": "Serologic  changes in hepatic, renal, cardiac  parameters", 
            "safety_issue": "No", 
            "time_frame": "weekly x 8 weeks"
        }, 
        "overall_contact": {
            "email": "M.Schachner@salk.at", 
            "last_name": "Michaela Schachner", 
            "phone": "001-43 0 662 4482 2898"
        }, 
        "overall_official": {
            "affiliation": "Medicizinische Universitatsklinik Hematologie,Internistische Onkologie", 
            "last_name": "Richard Greil, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Austria: Austrian Medicines and Medical Devices Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The primary objectives of this study are to determine in cancer patients the safety profile of increasing doses of intravenous liposomal curcumin until the maximum tolerated dose (MTD) is determined. This will be done by assessing clinical chemistry, hematology, EKGs and urine analyses, signs and physical symptoms of adverse events.", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "Eight(8) weeks"
            }, 
            {
                "description": "The primary objectives of this study are to determine in cancer patients the safety profile of increasing doses of intravenous liposomal curcumin until the maximum tolerated dose (MTD) is determined. This will be done by assessing clinical chemistry, hematology, EKGs and urine analyses, signs and physical symptoms of adverse events.", 
                "measure": "Deternmine the maximum tolerated dose of lipocurc", 
                "safety_issue": "Yes", 
                "time_frame": "in the cohort after eight ( 8) weeks of treatment"
            }, 
            {
                "description": "The primary objectives of this study are to determine in cancer patients the safety profile of increasing doses of intravenous liposomal curcumin until the maximum tolerated dose (MTD) is determined. This will be done by assessing clinical chemistry, hematology, EKGs and urine analyses, signs and physical symptoms of adverse events.", 
                "measure": "Maximum tolerated dose", 
                "safety_issue": "Yes", 
                "time_frame": "eight(8) weeks"
            }, 
            {
                "measure": "Maximum tolerated dose  defined by  < Grade 1  hematologic toxicity,", 
                "safety_issue": "Yes", 
                "time_frame": "Outcome measured  weekly x 8 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02138955"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The secondary objectives are to determine the PK profiles of increasing doses, up to the MTD of liposomal curcumin, and to record any evidence of beneficial effect  associated with the treatment.", 
                "measure": "Response by Recist criteria", 
                "safety_issue": "No", 
                "time_frame": "Eight(8) weeks"
            }, 
            {
                "description": "The secondary objectives are to determine the PK profiles of increasing doses, up to the MTD of liposomal curcumin, and to record any evidence of beneficial effect  associated with the treatment.", 
                "measure": "Tumor response by resist criteria", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "The secondary objectives are to determine the PK profiles of increasing doses, up to the MTD of liposomal curcumin, and to record any evidence of beneficial effect  associated with the treatment.", 
                "measure": "Tumor response", 
                "safety_issue": "No", 
                "time_frame": "Eight weeks"
            }, 
            {
                "description": "The secondary objectives are to determine the PK profiles of increasing doses, up to the MTD of liposomal curcumin, and to record any evidence of related beneficial effect  associated with the treatment.", 
                "measure": "Benefit", 
                "safety_issue": "No", 
                "time_frame": "Eight(8) weeks"
            }, 
            {
                "measure": "Objective change  in measurable tumor size by Resist criteria", 
                "safety_issue": "No", 
                "time_frame": "once after 8 weeky treatments"
            }
        ], 
        "source": "SignPath Pharma, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "SignPath Pharma, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}